Bob Cook
Director of Finance/CFO presso CHEETAH NET SUPPLY CHAIN SERVICE INC.
Profilo
Robert W.
Cook currently works at Cheetah Net Supply Chain Service, Inc., as Chief Financial Officer from 2022.
Mr. Cook also formerly worked at EpiCept Corp., as President, CEO, CFO, Secretary & Director from 2012 to 2013, The Chase Manhattan Bank NA, as Managing Director, Immune Pharmaceuticals, Inc., as Chief Financial Officer, Director & Senior VP from 2013 to 2014, W World Corp., as Chief Financial Officer & Executive Vice President from 1998 to 2004, RenovaCare, Inc., as Chief Financial Officer & Secretary from 2020 to 2021, GE Capital Commercial Finance, Inc., as Vice President-Healthcare Group, STRATA Skin Sciences, Inc., as Chief Financial Officer, Secretary & Treasurer from 2014 to 2016, CorMedix, Inc., as Chief Financial & Accounting Officer from 2017 to 2020, and Bioblast Pharma Ltd., as Chief Financial Officer in 2016.
Mr. Cook received his undergraduate degree in 1977 from Kogod School of Business.
Posizioni attive di Bob Cook
| Società | Posizione | Inizio |
|---|---|---|
| CHEETAH NET SUPPLY CHAIN SERVICE INC. | Director of Finance/CFO | 01/10/2022 |
Precedenti posizioni note di Bob Cook
| Società | Posizione | Fine |
|---|---|---|
| RENOVACARE, INC. | Director of Finance/CFO | 12/04/2021 |
| CORMEDIX INC. | Director of Finance/CFO | 31/01/2020 |
Bioblast Pharma Ltd.
 Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Director of Finance/CFO | 01/07/2016 |
| STRATA SKIN SCIENCES, INC. | Director of Finance/CFO | 01/01/2016 |
| IMMUNE PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/04/2014 |
Formazione di Bob Cook
| Kogod School of Business | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| W WORL | Health Technology |
| RENOVACARE, INC. | Health Technology |
| STRATA SKIN SCIENCES, INC. | Health Technology |
| CORMEDIX INC. | Health Technology |
| CHEETAH NET SUPPLY CHAIN SERVICE INC. | Industrial Services |
| Aziende private | 5 |
|---|---|
The Chase Manhattan Bank NA
 The Chase Manhattan Bank NA Major BanksFinance The Chase Manhattan Bank NA operates a commercial banking. It provides financial products, services, and advice, planning and treasury management services. The company is located in New York, NY. | Finance |
GE Capital Commercial Finance, Inc.
 GE Capital Commercial Finance, Inc. Investment ManagersFinance Part of GE Aerospace, GE Capital Commercial Finance, Inc. is an investment manager. The private company is based in Glendale, CA. | Finance |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
EpiCept Corp.
 EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Borsa valori
- Insiders
- Bob Cook
